No Data
Innovent Bio (01801.HK) and Beijing Aosaikang Pharmaceutical have reached a strategic cooperation on the lung cancer targeted drug Aiyixin.
Innovent Bio (01801.HK) and Beijing Aosaikang Pharmaceutical (002755.SZ) recently signed a cooperation agreement. The two parties will achieve exclusive commercial cooperation on the third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) targeted drug "Icotinib Tablet" (commodity name: Oyi Xin). Beijing Aosaikang Pharmaceutical will be the holder of the marketing authorization for the collaborative product, responsible for the commercial production and supply of the collaborative product, and will pay Innovent Bio sales and marketing service fees according to the cooperation agreement. Innovent Bio will obtain the exclusive promotion and sales rights of the collaborative product in China mainland, and will pay according to the cooperation agreement
REACH NEW HLDGS: SUPPLEMENTAL ANNOUNCEMENT IN RELATION TOTHE ANNUAL REPORT 2023
REACH NEW HLDGS: INTERIM REPORT 2024
Haitong Sec: The inventory of polyester filament factories continues to deplete, hoping for improved end demand.
Continuous destocking of filament inventory, haitong sec expects downstream demand to further improve with the approaching of the traditional peak season in september-october.
Reach New Holdings (08471) announced its interim results, with a net loss attributable to shareholders of 6.485 million yuan, a year-on-year increase of 419.2%.
Reach New Holdings (08471) released its six-month performance for the period ending June 30, 2024, with a revenue of 39.709 million...
REACH NEW HLDGS: INTERIM RESULTS ANNOUNCEMENTFOR THE SIX MONTHS ENDED 30 JUNE 2024
No Data
No Data